Drug Profile
R 105508
Latest Information Update: 02 Aug 2001
Price :
$50
*
At a glance
- Originator Sankyo
- Class
- Mechanism of Action Monoamine oxidase A inhibitors; Monoamine oxidase B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Parkinson's disease
Most Recent Events
- 02 Aug 2001 Discontinued-Preclinical for Parkinson's disease in Japan (Unknown route)
- 01 May 2001 New profile
- 01 May 2001 Preclinical development for Parkinson's disease in Japan (Unknown route)